-
公开(公告)号：US20230137343A1
公开(公告)日：2023-05-04
申请号：US17938545
申请日：2022-10-06
发明人： Kathleen BOYLE , Hangil PARK , Srinivas KOTHAKOTA , Mark SELBY , Thomas BRENNAN , Lewis T. WILLIAMS , Rosa Romano , Weijie Lan
摘要： The present invention relates to methods and combination therapies for enhancing the activity and function of non-B cell immune cells (such as T cells) using genetically modified B cells. These methods and combinations can be used, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like.
-
公开(公告)号：US11913023B2
公开(公告)日：2024-02-27
申请号：US17465759
申请日：2021-09-02
发明人： Kathleen Boyle , Hangil Park , Srinivas Kothakota , Mark Selby , Thomas Brennan , Lewis T. Williams
IPC分类号： C12N5/0781 , A61K35/17 , C07K16/30
CPC分类号： C12N5/0635 , A61K35/17 , C07K16/303 , C07K16/3069 , C07K2317/53 , C07K2317/622 , C07K2319/03 , C12N2510/00
摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
-
公开(公告)号：US20240002793A1
公开(公告)日：2024-01-04
申请号：US18314778
申请日：2023-05-09
发明人： Kathleen Boyle , Hangil Park , Srinivas Kothakota , Mark Selby , Thomas Brennan , Lewis T. Williams
IPC分类号： C12N5/0781 , A61K35/17 , C07K16/30
CPC分类号： C12N5/0635 , A61K35/17 , C07K16/303 , C07K16/3069 , C07K2317/53 , C07K2319/03 , C12N2510/00 , C07K2317/622
摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
-
公开(公告)号：US20240034995A1
公开(公告)日：2024-02-01
申请号：US18316198
申请日：2023-05-11
发明人： Kathleen Boyle , Hangil Park , Srinivas Kothakota , Mark Selby , Thomas Brennan , Lewis T. Williams
IPC分类号： C12N5/0781 , A61K35/17 , C07K16/30
CPC分类号： C12N5/0635 , A61K35/17 , C07K16/303 , C07K16/3069 , C07K2317/53 , C07K2319/03 , C12N2510/00 , C07K2317/622
摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
-
公开(公告)号：US12037604B2
公开(公告)日：2024-07-16
申请号：US18316198
申请日：2023-05-11
发明人： Kathleen Boyle , Hangil Park , Srinivas Kothakota , Mark Selby , Thomas Brennan , Lewis T. Williams
IPC分类号： C12N5/0781 , A61K35/17 , C07K16/30
CPC分类号： C12N5/0635 , A61K35/17 , C07K16/303 , C07K16/3069 , C07K2317/53 , C07K2317/622 , C07K2319/03 , C12N2510/00
摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
-
公开(公告)号：US20220331362A1
公开(公告)日：2022-10-20
申请号：US17724423
申请日：2022-04-19
发明人： Thomas Brennan
IPC分类号： A61K35/17 , C12N5/0781 , C12N15/62 , C12N15/86 , C07K14/705 , C07K16/28 , C07K14/715 , C07K14/47
摘要： The invention disclosed herein relates to improved methods for expanding cell populations, particularly B cell populations. The invention further relates to improved B-cell expansion media, compositions comprising expanded B cells and methods of using such expanded B cells. The invention further relates to methods of treating diseases or disorders wherein a population of B cells is obtained and cultured, and wherein said B cells are engineered to express a payload and/or a chimeric receptor, and wherein said B cells are administered to a subject.
-
公开(公告)号：US20220073876A1
公开(公告)日：2022-03-10
申请号：US17465759
申请日：2021-09-02
发明人： Kathleen Boyle , Hangil Park , Srinivas Kothakota , Mark Selby , Thomas Brennan , Lewis T. Williams
IPC分类号： C12N5/0781 , A61K35/17 , C07K16/30
摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.012 秒)
